NO20010603L - 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister - Google Patents
2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonisterInfo
- Publication number
- NO20010603L NO20010603L NO20010603A NO20010603A NO20010603L NO 20010603 L NO20010603 L NO 20010603L NO 20010603 A NO20010603 A NO 20010603A NO 20010603 A NO20010603 A NO 20010603A NO 20010603 L NO20010603 L NO 20010603L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- orl
- aromatic
- unsubstituted
- piperidylbenzimidazole
- Prior art date
Links
- 108010020615 nociceptin receptor Proteins 0.000 title abstract 2
- -1 2-substituted-1-piperidylbenzimidazole compounds Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En forbindelse med formel (I) eller et farmasøytisk akspetabelt salt derav, hvori R er usubstituert, mono-, di- eller trisubstituert (C3-Cn)cykloalkyl eller (C3-Cn)cykloalkenyl eller lignende, A er usubstituert (CrC7)alkyl eller (C2-C5)alkenyl, eller usubstituert mono-, di- eller trisubstituert aryl, eller aromatisk-heterocyklisk eller lignende. Y er hydrogen, halogen, amino eller merkapto, eller usubstituert mono-, 3- eller trisubstituert (Ci-Cio)alkyl-M-, (C3-C7)cykloalkyl-M-, (C2-C6)alkenyl-M-, (Ci-C4)a!kyl-NM-((Ci-C4)alkyl)-M-1di(Ci-C4)alkyl-N-((Ci-Cs)alkyl-M-1aryl-M-1 aromatisk eller uaromatisk heterocyklisk-M-, aryl-(Ci-C5)alkyl-M- eller aromatisk, uaromatisk heterocyklisk^CrCjJalkyl-M-, hvori M er en kovalent binding O, S, NH eller lignende; Z1, Z2, Z3 og Z4 er hydrogen eller lignende, har ORL-1 reseptor agonistaktivitet og er nyttig som smertestillende midler eller lignende i pattedyr.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB98/01206 | 1998-08-06 | ||
| PCT/IB1999/001239 WO2000008013A2 (en) | 1998-08-06 | 1999-07-05 | 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20010603D0 NO20010603D0 (no) | 2001-02-05 |
| NO20010603L true NO20010603L (no) | 2001-04-05 |
Family
ID=11004738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010603A NO20010603L (no) | 1998-08-06 | 2001-02-05 | 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister |
Country Status (44)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340681B1 (en) * | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| ATE306488T1 (de) * | 2000-01-05 | 2005-10-15 | Pfizer | Benzimidazol-verbindungen zur verwendung als orl1-rezeptor-antagonisten |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| AU2002224038B2 (en) * | 2000-11-15 | 2006-03-09 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| EP2172468A1 (en) | 2001-04-18 | 2010-04-07 | Euro-Celtique S.A. | Benzimidazolone compounds |
| PT1385515E (pt) | 2001-04-18 | 2008-09-15 | Euro Celtique Sa | Compostos de espiropirazole |
| BR0209128A (pt) * | 2001-04-18 | 2005-11-01 | Euro Celtique Sa | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos |
| ES2322158T3 (es) * | 2001-04-18 | 2009-06-17 | Euro-Celtique S.A. | Derivados 1-(4-piperidinil)-1,3-dihidro-2h-indol-2-ona y compuestos afines como analogos de la nociceptina y ligandos del orl-1 para el tratamiento del dolor. |
| US6828440B2 (en) | 2001-04-18 | 2004-12-07 | Euro-Celtique, S.A. | Spiroindene and spiroindane compounds |
| US20030040479A1 (en) * | 2001-07-02 | 2003-02-27 | Omeros Corporation | Rotational intrathecal analgesia method and device |
| EP1406629A1 (en) * | 2001-07-02 | 2004-04-14 | Omeros Corporation | Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
| SE0103818D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| WO2003049736A1 (en) * | 2001-12-11 | 2003-06-19 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
| WO2003082333A1 (en) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remedy for sleep disturbance |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| DE10252665A1 (de) * | 2002-11-11 | 2004-06-03 | Grünenthal GmbH | 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate |
| DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| GB0315203D0 (en) * | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| US8067603B2 (en) | 2003-09-25 | 2011-11-29 | Solvay Pharmaceuticals B.V. | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| WO2005060947A2 (en) * | 2003-12-19 | 2005-07-07 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| WO2006038738A1 (ja) * | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| ATE488235T1 (de) | 2005-01-11 | 2010-12-15 | Neurosearch As | Neue 2-amino-benzimidazolderivate und ihre verwendung als modulatoren calciumaktivierter kaliumkanäle mit geringer leitfähigkeit |
| CA2654666A1 (en) * | 2006-07-03 | 2008-01-10 | Neurosearch A/S | Pharmaceutical compositions |
| NZ578078A (en) | 2007-01-16 | 2011-11-25 | Purdue Pharma Lp | Heterocyclic-substituted piperidine as orl-1 ligands |
| MX379353B (es) | 2007-08-31 | 2025-03-10 | Purdue Pharmal P | Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos. |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| MY153948A (en) | 2008-07-21 | 2015-04-15 | Purdue Pharma Lp | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| KR20130108543A (ko) | 2010-08-05 | 2013-10-04 | 암젠 인코포레이션 | 역형성 림프종 키나제를 억제하는 벤즈이미다졸 및 아자벤즈이미다졸 화합물 |
| WO2013103598A2 (en) | 2012-01-06 | 2013-07-11 | Novus International Inc. | Sulfoxide-based surfactants |
| EP2812372B1 (en) | 2012-02-09 | 2018-09-26 | Novus International Inc. | Heteroatom containing cyclic dimers |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| US9452143B2 (en) | 2012-07-12 | 2016-09-27 | Novus International, Inc. | Matrix and layer compositions for protection of bioactives |
| US9085561B2 (en) * | 2012-07-30 | 2015-07-21 | Purdue Pharma L.P. | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators |
| WO2014102594A2 (en) * | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Substituted benzimidazole-type piperidine compounds and uses thereof |
| EP2976077A4 (en) | 2013-03-22 | 2016-11-30 | Scripps Research Inst | SUBSTITUTED BENZIMIDAZOLE AS NOCICEPTIN RECEPTOR MODULATORS |
| SG11201607706SA (en) * | 2014-03-20 | 2016-10-28 | Capella Therapeutics Inc | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| CN112707851A (zh) | 2015-11-12 | 2021-04-27 | 诺华丝国际股份有限公司 | 作为溶剂的含硫化合物 |
| US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3318900A (en) * | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| JPS5297978A (en) * | 1976-06-02 | 1977-08-17 | Yoshitomi Pharmaceut Ind Ltd | Preparation of alicyclic derivatives |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| ATE233812T1 (de) | 1995-08-15 | 2003-03-15 | Euroscreen Sa | Peptide mit pronociceptiveigenschaften |
| US5866346A (en) | 1995-09-27 | 1999-02-02 | Indiana Unversity Foundation | Methods of using dynorphins as ligands for XOR1 receptor |
| EP0898568B1 (en) * | 1996-04-19 | 2006-10-04 | Neurosearch A/S | 1-(4-piperidyl)-benzimidazoles having neurotrophic activity |
| EP0813065A3 (en) | 1996-06-13 | 1998-07-22 | F. Hoffmann-La Roche Ag | Modulation of LC132 (opioid-like) receptor function |
| EP0829481A1 (en) * | 1996-09-16 | 1998-03-18 | Pfizer Inc. | Morphinan hydroxamic acid compounds |
| US5718912A (en) * | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| ATE276242T1 (de) | 1997-05-30 | 2004-10-15 | Banyu Pharma Co Ltd | 2-oxoimidazol-derivate |
| WO1999003880A1 (en) | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | Nociceptin analogues |
| US5929035A (en) | 1998-04-14 | 1999-07-27 | Regents Of The University Of Michigan | Methods of treating intestinal disorders |
| ID29137A (id) | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
-
1999
- 1999-06-25 MA MA25646A patent/MA26659A1/fr unknown
- 1999-06-28 TW TW088110899A patent/TW513424B/zh not_active IP Right Cessation
- 1999-07-05 IL IL14102999A patent/IL141029A0/xx unknown
- 1999-07-05 NZ NZ509299A patent/NZ509299A/en not_active Application Discontinuation
- 1999-07-05 CN CN99810857A patent/CN1317968A/zh active Pending
- 1999-07-05 HK HK02101444.8A patent/HK1040188A1/zh unknown
- 1999-07-05 ID IDW20010284D patent/ID27212A/id unknown
- 1999-07-05 AU AU43859/99A patent/AU749166B2/en not_active Ceased
- 1999-07-05 CA CA002339621A patent/CA2339621C/en not_active Expired - Fee Related
- 1999-07-05 SI SI9930151T patent/SI1102762T1/xx unknown
- 1999-07-05 AP APAP/P/2001/002063A patent/AP2001002063A0/en unknown
- 1999-07-05 GE GEAP19995740A patent/GEP20033000B/en unknown
- 1999-07-05 TR TR2001/00403T patent/TR200100403T2/xx unknown
- 1999-07-05 BR BR9912778-4A patent/BR9912778A/pt not_active Application Discontinuation
- 1999-07-05 DK DK99926688T patent/DK1102762T3/da active
- 1999-07-05 WO PCT/IB1999/001239 patent/WO2000008013A2/en not_active Ceased
- 1999-07-05 EE EEP200100075A patent/EE200100075A/xx unknown
- 1999-07-05 PL PL99346211A patent/PL346211A1/xx not_active Application Discontinuation
- 1999-07-05 OA OA1200100031A patent/OA11590A/en unknown
- 1999-07-05 YU YU8201A patent/YU8201A/sh unknown
- 1999-07-05 SK SK160-2001A patent/SK1602001A3/sk unknown
- 1999-07-05 HU HU0103567A patent/HUP0103567A3/hu unknown
- 1999-07-05 CZ CZ2001397A patent/CZ2001397A3/cs unknown
- 1999-07-05 HN HN1999000105A patent/HN1999000105A/es unknown
- 1999-07-05 AT AT99926688T patent/ATE227716T1/de not_active IP Right Cessation
- 1999-07-05 EP EP99926688A patent/EP1102762B1/en not_active Expired - Lifetime
- 1999-07-05 DE DE69903953T patent/DE69903953T2/de not_active Expired - Fee Related
- 1999-07-05 PT PT99926688T patent/PT1102762E/pt unknown
- 1999-07-05 TN TNTNSN99142A patent/TNSN99142A1/fr unknown
- 1999-07-05 ES ES99926688T patent/ES2185357T3/es not_active Expired - Lifetime
- 1999-07-05 HR HR970081A patent/HRP20010089B1/xx not_active IP Right Cessation
- 1999-07-05 EA EA200100104A patent/EA200100104A1/ru unknown
- 1999-07-05 JP JP2000563646A patent/JP3367945B2/ja not_active Expired - Fee Related
- 1999-07-06 AR ARP990103264A patent/AR018686A1/es active IP Right Grant
- 1999-07-15 PE PE1999000717A patent/PE20000868A1/es not_active Application Discontinuation
- 1999-07-16 PA PA19998477701A patent/PA8477701A1/es unknown
- 1999-07-16 SV SV1999000099A patent/SV1999000099A/es not_active Application Discontinuation
- 1999-08-05 US US09/369,208 patent/US6172067B1/en not_active Expired - Fee Related
- 1999-08-06 GT GT199900125A patent/GT199900125A/es unknown
- 1999-08-13 UY UY25659A patent/UY25659A1/es not_active Application Discontinuation
-
2001
- 2001-01-16 IS IS5812A patent/IS5812A/is unknown
- 2001-02-01 ZA ZA200100900A patent/ZA200100900B/xx unknown
- 2001-02-05 NO NO20010603A patent/NO20010603L/no not_active Application Discontinuation
- 2001-03-01 BG BG105301A patent/BG105301A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20010603L (no) | 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister | |
| ATE401066T1 (de) | Methoden zur behandlung der essstörungen | |
| DK0525123T3 (da) | Antiatherosklerotiske og antithrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner | |
| DK1076644T3 (da) | N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser | |
| NZ506679A (en) | HIV inhibiting pyrimidine derivatives | |
| TR200002480T2 (tr) | İzaşemi tedavisi için guanidin türevleri | |
| HUP0201659A2 (hu) | Kristályos benzimidazol-vegyület | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| DK0406623T3 (da) | Polyasparaginsyrederivater som overtræksmiddel til lægemiddelformer og levnedsmidler | |
| MY146532A (en) | Thiazole derivative | |
| BR0014651A (pt) | Inibidores de adesão de célula mediada por "alfa" l beta2 | |
| DK359289A (da) | 4-oxoquinolin-3-carboxylsyrederivater og fremgangsmaade til fremstilling deraf samt deres anvendelse | |
| TR200103683T2 (tr) | Indol türevleri ve bu türevlerin diğer uygulamaların yanısıra osteoporoz tedavisinde kullanımı | |
| TW200642689A (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
| WO2001062705A3 (en) | Aminoalcohol derivatives | |
| GB0402809D0 (en) | Chemical compounds | |
| DK1789019T3 (da) | Pulvere indeholdende hidtil ukendte oligosaccharidblandinger og fremgangsmåder til fremstilling af disse | |
| NO20050666L (no) | 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer | |
| ATE238274T1 (de) | Naphthalin derivate | |
| NO20031841L (no) | Triazolderivater og farmasöytiske preparater inneholdende disse | |
| SE9802538D0 (sv) | New pharmaceutically active compounds | |
| NO973242L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti | |
| TR199903249T2 (xx) | �l-5 inhibit�rleri olarak 6-Azaurasil t�revleri. | |
| DK0742716T3 (da) | Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid | |
| NO994303L (no) | Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |